Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Poor Outcome of Intestinal Ischemic Manifestations of COVID-19

Lorenzo Norsa,1 Pietro Andrea Bonaffini,2,3 Amedeo Indriolo,4 Clarissa Valle,2,3 Aurelio Sonzogni,5 and Sandro Sironi2,3

Methods

We retrospectively collected clinical records of SARS-CoV-2–positive patients diagnosed with intestinal ischemia upon emergency department admission or during their hospitalization in the period from March 1 to April 30, 2020 in Papa Giovanni XXIII Hospital. Those patients were compared with patients diagnosed with intestinal ischemia in a pre–COVID-19 period from January 1 to February 29, 2020. The protocol was approved by the local ethical committee.

Results

We found that 7 patients fulfilled clinical and radiologic criteria for intestinal ischemia (Table 1). All patients presented with gastrointestinal (GI) symptoms. Six were evaluated with abdominal contrast-enhanced computed tomography scan. Two demonstrated evidence of ischemic colitis with marked wall edema and layered enhancement involving either the whole large bowel or the right colon. Four had evidence of ischemia (thin wall with reduced enhancement or signs of pneumatosis intestinalis) involving either the small bowel or the right transverse colon (Supplementary Figure 1). Among the latter 4, thromboembolic filling defects in the inferior vena cava and superior mesenteric vein were found in 1. Two of the 6 patients also showed unexplained splenic infarcts. One additional patient was diagnosed with ischemic colitis through endoscopy (Supplementary Figure 2). D-dimer was tested in 6 patients and results were markedly elevated in all of them. Six of 7 patients also underwent a thoracic computed tomography scan that showed pulmonary thromboembolism in 1 patient. Four of 7 patients (57%) died either in the first 48 hours after admission (n = 3) or after surgery (n = 1). In the study period pre–COVID-19, we identified 3 patients who fulfilled the enrollment criteria of intestinal ischemia. This accounts for an increase of 133% in intestinal ischemia admitted to our hospital during the COVID-19 pandemic. One patient died from the sequelae of small bowel resection due to ischemia. The other 2 recovered from ischemic colitis. All 3 patients had important comorbidities, including chronic renal insufficiency on dialysis for the first patient who died, Hodgkin’s lymphoma in the second patient, and type 2 diabetes and hypertension in the third patient.

Mortality among patients with COVID-19–related intestinal ischemia was 1.7-fold higher (95% confidence interval, 0.3–9.6) than in the remnant cohort.

Discussion

This is, to our knowledge, the first report exploring clinical features and outcomes of patients with COVID-19 presenting with intestinal ischemia. Our study confirms a previous case report on the association of intestinal ischemia with COVID-19 and demonstrates an increased mortality rate in patients with intestinal ischemia in the COVID-19 period compared with SARS-CoV-2–negative patients.

GI symptoms have been described in 10% of patients with COVID-19.4 In most cases these symptoms are mild and self-limiting, even if they seem to increase the risk of complications.4 We found that GI symptoms at admission could also be the expression of an underlying intestinal ischemia.

A state of hypercoagulability has been found via thromboelastography in most of the COVID-19 patients admitted to intensive care units.5 Quantitative D-dimer has already been proposed as the best single marker of hypercoagulability in COVID-19 patients, as well as a negative prognostic marker.5

Abbreviations used in this paper: GI, gastrointestinal; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
In addition, a recent publication has proposed down-regulation of angiotensin-converting-enzyme 2 as a possible pathogenetic hypothesis for acute vascular damage. The presence of angiotensin-converting-enzyme 2 protein, which has been proved to be a cell receptor for SARS-CoV-2, has been demonstrated by immunofluorescence in the gastrointestinal epithelium.

The increase in mortality rate of this series accounts for part of the +568% mortality of Bergamo province reported in the first trimester of 2020 compared with the first trimester of the previous 4 years (2015–2019).

No final conclusions can be drawn from such a small number of patients due to the ongoing characteristic of the pandemic. However, our experience suggests that a high level of suspicion for intestinal ischemia should be maintained in COVID-19 patients presenting with GI symptoms or with arising abdominal pain because this complication could account for an increase mortality risk. Nevertheless, in this subset, a D-dimer elevation should not only trigger prompt prophylactic use of anticoagulants, but also lead to consider an early abdominal computed tomography scan in patients with suggestive symptoms or biochemical markers of intestinal ischemia. Additional analysis will help to define the role of SARS-CoV-2 in the pathogenesis of such a detrimental manifestation.

Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at http://dxdoi.org/10.1053/j.gastro.2020.06.041.

References
1. Guan W-J, et al. N Engl J Med 2020;382:1708–1720.
2. Bhayana R, et al. Radiology 2020 May 11:201908.
3. Parry AH, et al. Acad Radiol 2020;27:1190.
4. Mao R, et al. Lancet Gastroenterol Hepatol 2020;5:667–678.
5. Panigada M, et al. J Thromb Haemost 2020;18:1738–1742.
6. Thachil J, et al. J Thromb Haemost 2020;18:1023–1026.
7. Giardini V, et al. Am J Hematol 2020;95:E188–E191.
8. Xiao F, et al. Gastroenterology 2020;158:1831–1833.e3.
9. Ufficio Stampa Istat. Available at: https://www.istat.it/it/files/2020/05/Rapporto_Istat_ISS.pdf.

Table 1. Characteristics of Patients With Intestinal Ischemia During COVID-19 Infection

| Patient no. | Age, y | Sex | Ongoing ACT/APT | Entry symptoms | CT/endo findings | CT/endoscopy findings | CT/endoscopy: ischemic colitis | CT: rectal bleeding; CT: ischemic colitis (right colon) | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Outcome |
|------------|--------|-----|-----------------|----------------|----------------|-----------------------|-----------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------|
| 1          | 85     | Male| ASA             | Low GI bleeding| Loss of appetite, vomiting, low GI bleeding | CT: ischemic colitis (right colon) | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Discharged |
| 2          | 71     | Female| ASA | Loss of appetite, vomiting, low GI bleeding | Endoscopy: ischemic colitis | CT: ischemic colitis | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Discharged |
| 3          | 69     | Male| ASA | Abdominal pain | CT: rectal bleeding; CT: ischemic colitis | CT: ischemic colitis | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Death |
| 4          | 79     | Female| LMWH| Abdominal pain | Lower limb pain | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Discharged |
| 5          | 63     | Male| LMWH | Abdominal pain and vomiting | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Discharged |
| 6          | 82     | Male| LMWH | Abdominal pain and vomiting | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Death |
| 7          | 83     | Female| LMWH | Abdominal pain and vomiting | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SB occlusion; splenic infarcts | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | CT: SB ischemia with SMV and MC thrombosis | Death |

ACT, anticoagulant therapy; APT, antiplatelet therapy; ASA, acetylsalicylic acid; CT, computed tomography; DOAC, direct oral anticoagulant; GI, gastrointestinal; IVC, inferior vena cava; LMWH, low-molecular-weight heparin; SB, small bowell; SMV, superior mesenteric vein.
CRediT Authorship Contributions
Lorenzo Norsa, MD, PhD (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Writing – original draft: Lead). Bonaffini Pietro, MD (Data curation: Lead; Methodology: Lead; Writing – review & editing: Lead). Amedeo Indriolo, MD (Data curation: Lead; Writing – review & editing: Lead). Clarissa Valle, MD (Data curation: Lead; Methodology: Lead; Writing – review & editing: Lead). Sonzogni Aurelio, MD (Data curation: Lead; Supervision: Lead; Writing – review & editing: Lead). Sandro Sironi, MD (Supervision: Equal; Writing – review & editing: Equal).

Conflicts of interest
The authors disclose no conflicts.
**Supplementary Figure 1.** Computed tomography (CT) scan findings of patient 5. Axial (A) and coronal (B) images show pathologic dilation of the transverse colon (measuring up to 10 cm in caliber, A) associated with thin wall and parietal pneumatoses (arrow, B). Also, the ascending colon was involved (not completely shown). There were no signs of pneumoperitoneum or main mesenteric vessels thrombosis; the small bowel loops were normal. Concomitantly, a myocardial infarct (arrow, C) and a focal ischemic lesion in the spleen were noted (arrow, D). Patient was admitted to intensive care unit and died 1 day after the CT scan.

**Supplementary Figure 2.** Endoscopic appearance of transverse colon of patient 2.